leadf
logo-loader
viewAchillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals receives key US patent for Hep C drug

drug_research_350_4d80c45f3018c.jpg

Drug developer Achillion Pharmaceuticals (NASDAQ:ACHN) said Wednesday that it has received a US patent for ACH-1625, an investigational drug designed to treat the hepatitis C virus.

The new patent, which covers composition of matter and method of use, has a term until 2029, the company said.

"This key patent grant provides a cornerstone for Achillion's intellectual property portfolio for ACH-1625 and a number of structurally related compounds," said president and CEO Michael D. Kishbauch.

The company is expecting phase 2 clinical trial results for ACH-1625 in the next months, and is also planning to move two other compounds into phase 1 trials during the first half of the year.

Quick facts: Achillion Pharmaceuticals, Inc.

Price: - -

NASDAQ:ACHN
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Condor Gold adds second drill rig as they look to ramp up drill program at...

Condor Gold (AIM: CNR- TSE: COG) CEO Mark Child joined Steve Darling from Proactive with news the company has added a second drill rig on their La India Project, in Nicaragua. Child telling Proactive, this rig will help speed up infill drilling on their current 4000-metre program. The...

10 hours, 36 minutes ago

2 min read